Nishio, MakotoBarlesi, FabriceWest, HowardBall, SimonBordoni, RodolfoCobo, ManuelLongeras, Pascale DubrayGoldschmidt, JeromeNovello, SilviaOrlandi, FranciscoSanborn, Rachel ESzalai, ZsuzsannaUrsol, GrigoriyMendus, DianaWang, LijiaWen, XiaohuiMcCleland, MarkHoang, TienPhan, SeeSocinski, Mark A2023-02-092023-02-092020-12-14Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, et al. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. J Thorac Oncol. 2021 Apr;16(4):653-664http://hdl.handle.net/10668/16813We report the final results of the phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP) in patients with nonsquamous NSCLC. Chemotherapy-naive patients with stage IV nonsquamous NSCLC without sensitizing EGFR or ALK genetic alterations were randomized in a one-to-one ratio to receive four or six cycles of carboplatin or cisplatin plus pemetrexed (PP) or APP every 3 weeks, followed by maintenance therapy with atezolizumab plus pemetrexed or pemetrexed alone. Co-primary end points were overall survival (OS) and investigator-assessed progression-free survival (PFS). The intention-to-treat population included 578 patients (APP, n = 292; PP, n = 286). At the primary PFS analysis (May 22, 2018; median follow-up, 14.8 mo), APP exhibited significant PFS improvement versus PP (median = 7.6 versus 5.2 mo, stratified hazard ratio [HR] = 0.60, 95% confidence interval [CI]: 0.49-0.72, p IMpower132 met its co-primary PFS end point but not its co-primary OS end point, with numerical improvement for OS in the APP arm. APP had a manageable safety profile, with no new or unexpected safety signals identified.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/AtezolizumabLung cancerNonsquamousNon–small cellAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungCisplatinHumansLung NeoplasmsPemetrexedresearch article33333328open accessCisplatinoCarboplatinoInforme de investigaciónIntervalos de confianzaQuimioterapia10.1016/j.jtho.2020.11.0251556-1380http://www.jto.org/article/S155608642031100X/pdf